Widespread availability of real-world data has enabled the generation of evidence and insights that benefit patients, providers, plans, and industry. Explore our real-world data analyses to support your strategic decisions.
In 2012, experts predicted that artificial Intelligence (AI) would eventually replace as much as 80% of current clinical practice by physicians. While AI has certainly expanded in healthcare—especially during the COVID-19 pandemic—the last few years have included some eventful setbacks in the use of AI across several sectors of the economy, including healthcare.
Data-Driven Research Presented at Academy of Managed Care Pharmacy (AMCP), ISPOR Annual Meeting and Key Spring Conferences Powered by Inovalon’s MORE2 Registry® Dataset
Tune into our first episode in the Avalere Health Essential Voice podcast series focused on disease education. In this segment, our experts discuss recent research that, using Medicare fee-for-service claims data, studied healthcare utilization, costs, outcomes, and other characteristics of patients who received CAR T-cell therapy for large B-cell lymphoma.
Tune into our first episode in the Avalere Health Essential Voice series focused on disease education. In this segment, our experts discuss recent research that, using Medicare fee-for-service claims data, studied healthcare utilization, costs, outcomes, and other characteristics of patients who received CAR T-cell therapy for large B-cell lymphoma.
Internet of Things (IoT) is a catch-all term that refers to any device that can connect to a network (including the Internet) and communicate with other devices.
On November 4, Avalere experts presented “Development of a Claims-Based Algorithm to Identify Patients with Agitation in Alzheimer’s Dementia” at the Gerontological Society of America Annual Scientific Meeting.
Tune into another episode of Start Your Day with Avalere. In this segment, health plan experts delve into the strategic opportunities the federal government’s interoperability requirements present and consider which mandates might be coming down the pike.
Tune into another episode of Start Your Day with Avalere. In this segment, health plan experts delve into the federal government’s interoperability requirements and how plans are navigating these changes.
On June 9, Avalere experts discussed new data analytics and approaches for evaluating value-based topics in healthcare in the “New Data Approaches for Novel Curative Therapies & APMs” webinar. They examined the current approaches to assessing the value of treatments, novel curative therapy affordability and access, and the role of data in healthcare decision-making.
Avalere experts discussed new data analytics and health economics and outcomes research approaches for evaluating key value-based topics in healthcare, including novel curative therapy affordability and access, alternative payment models, and the increasingly important role of real-world evidence in healthcare decision-making.
Recurring episodes of clostridioides difficile (c diff) create significant added healthcare burden and costs to society and lead to avoidable adverse outcomes in the Medicare population
The collaboration leverages the Inovalon MORE2 Registry® payer-sourced dataset and Corrona’s platform of clinical registries to enable data-driven insights on the treatment of autoimmune diseases from both clinical and health economic perspectives.
Rising healthcare costs and the increased prevalence of chronic disease in the US are incentivizing stakeholders to develop new solutions to tackle these issues. Many have turned to digital health innovations like mobile health applications to facilitate care prevention and management for chronic disease, but significant gaps remain in their ability to be used in real-world practice.
As the shape and scope of America’s learning health system evolves, Avalere partners with industry leaders, engaging multiple stakeholders to formulate patient registry strategies that develop, evaluate, and utilize registry data – and help improve care in real time.
Avalere research recently published in ClinicoEconomics and Outcomes Research compared patient characteristics and real-world outcomes in 2 distinct high-risk cohorts of patients with serious mental illness (SMI), including patients with a hospitalization related to SMI (recently discharged) and patients newly diagnosed with SMI (early episode). The research included 51,705 patients with bipolar disorder, major depressive disorder, and schizophrenia.
Digital health remains a powerful focal point in the push towards value-based healthcare. Across multiple domains, emerging technologies provide promising strategies for delivering more effective, efficient, and personalized care.
The rapid expansion of artificial intelligence (AI) across healthcare holds the promise of dramatically altering not only diagnosis and treatment but also research, risk assessment, drug development, care management, and even insurance and payment systems.
Electronic health record (EHR) platforms continue to accelerate the transformation of healthcare by streamlining access to patient records, improving clinical outcomes, and fostering better decision-making at the point of care.
Remote patient monitoring (RPM) provides an opportunity to diagnose and treat patients facing neurological diseases. Given that multiple sclerosis (MS), Parkinson’s disease, and epilepsy require intervention from specialized care teams, effective management of these chronic neurological conditions can be supported through RPM to improve patient outcomes. Although RPM has been shown to be a complement and in some cases an alternative to office-based care, reimbursement and coverage barriers remain.
On Saturday, December 7, Karl Kilgore discussed “Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs” during a press briefing at the American Society of Hematology’s Annual Meeting.